XML 54 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Edwards Lifesciences conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and operating income. The accounting policies of the segments are the same as those described in Note 2. Segment net sales and segment operating income are based on internally derived foreign exchange rates and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. There were no customers that represented 10% or more of the Company's total net sales.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate research and development expenses, manufacturing variances, corporate headquarters costs, net interest income, global marketing expenses, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment operating income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information.
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Years Ended December 31,
 202320222021
Segment Net Sales   
United States$3,508.7 $3,132.6 $2,963.1 
Europe1,337.4 1,213.7 1,099.6 
Japan436.7 559.3 528.0 
Rest of World716.9 610.7 533.2 
Total segment net sales$5,999.7 $5,516.3 $5,123.9 
Segment Operating Income  
United States$2,306.1 $2,130.9 $2,051.0 
Europe709.5 652.2 569.1 
Japan259.1 376.7 348.0 
Rest of World310.4 247.7 185.2 
Total segment operating income$3,585.1 $3,407.5 $3,153.3 

The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Years Ended December 31,
 202320222021
Net Sales Reconciliation   
Segment net sales$5,999.7 $5,516.3 $5,123.9 
Foreign currency5.1 (133.9)108.6 
Consolidated net sales$6,004.8 $5,382.4 $5,232.5 
Pre-tax Income Reconciliation  
Segment operating income$3,585.1 $3,407.5 $3,153.3 
Unallocated amounts:
Corporate items(1,920.9)(1,714.1)(1,613.8)
Special charge and separation costs(17.2)(60.7)— 
Intellectual property agreement and litigation expense(203.5)(15.8)(20.6)
Change in fair value of contingent consideration liabilities26.2 35.8 124.1 
Foreign currency64.4 95.8 47.3 
Consolidated operating income1,534.1 1,748.5 1,690.3 
Non-operating income64.0 18.9 11.7 
Consolidated pre-tax income$1,598.1 $1,767.4 $1,702.0 
Enterprise-Wide Information
(in millions)

Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements.

 As of or for the Years Ended December 31,
 202320222021
Net Sales by Geographic Region   
United States$3,508.7 $3,132.6 $2,963.1 
Europe1,334.5 1,174.8 1,190.3 
Japan452.4 473.6 528.9 
Rest of World709.2 601.4 550.2 
$6,004.8 $5,382.4 $5,232.5 
Net Sales by Major Product Group  
Transcatheter Aortic Valve Replacement$3,879.8 $3,518.2 $3,422.5 
Transcatheter Mitral and Tricuspid Therapies197.6 116.1 86.0 
Surgical Structural Heart999.3 893.1 889.1 
Critical Care928.1 855.0 834.9 
$6,004.8 $5,382.4 $5,232.5 
Long-lived Tangible Assets by Geographic Region   
United States$1,269.7 $1,188.5 $1,195.8 
Europe196.4191.8197.9
Japan23.813.219.7
Rest of World353.5331.6335.5
$1,843.4 $1,725.1 $1,748.9